Shanghai Henlius Biotech Inc. has announced IND approval by the FDA for HLX-42 for injection, an antibody-drug conjugate (ADC) developed under a collaboration between Henlius and Medilink Therapeutics.
Myricx Bio (Myricx Pharma Ltd.) and Wuxi Biologics Co. Ltd. have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on Wuxi Bio's integrated technology platforms.
Medicovestor Inc. has successfully completed an oversubscribed seed financing round with the aim of advancing its antibody-drug conjugate (ADC) platforms and drug candidates.
Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a strategic collaboration with Genequantum Healthcare (Suzhou) Co. Ltd. to advance the early discovery of next-generation bioconjugates.
Protein tyrosine kinase 7 (PTK7) is a pseudo tyrosine kinase overexpressed in many cancer types such as ovarian, triple-negative breast cancer (TNBC), non-small-cell lung cancer, small-cell lung cancer and bladder cancer, but limited expression in normal tissues.
Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Doma Biopharmaceutical (Suzhou) Co. Ltd. reported the discovery and preclinical data of DM-005, a novel fully human EGFR × MET bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.
Debiopharm Research & Manufacturing SA has disclosed new antibody-drug conjugates consisting of monoclonal antibodies targeting CD37 covalently linked to a cytotoxic agent through a linker.
Researchers from Ambrx Inc. and Novocodex Biopharmaceuticals Co. Ltd. presented preclinical data for ARX-305, a next-generation anti-CD70 antibody-drug conjugate (ADC), being developed for the treatment of CD70-expressing cancers.
Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers.
Researchers from Shanghai Henlius Biotech Inc. presented the discovery and preclinical characterization of HLX-42, a next-generation EGFR-targeting antibody-drug conjugate (ADC) being developed for the treatment of cancer.
RSS
